Drugs / VidPrevtyn Beta
Regulatory milestones approvals, filings & regulatory actions · 2 recorded
| Milestone | Jurisdiction | Brand | Indication | Date | Sentence it was read from |
|---|---|---|---|---|---|
| Withdrawn | EU (EMA) | VidPrevtyn Beta | — | 2024-03-18 | europa.eu ↗ |
| Approved | EU (EMA) | VidPrevtyn Beta | — | 2022-11-10 | europa.eu ↗ |
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 3 | NCT05749926 | May → Jul 2023 | COVID-19 | Assistance Publique - Hôpitaux de Paris | Unknown | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | VidPrevtyn Beta | “VidPrevtyn® Beta vaccine (Sanofi/GSK)” NCT05749926 ↗ |
| Modality | Protein / enzyme biologic | “the Beta-variant recombinant protein booster vaccine (VidPrevtyn Beta, Sanofi)” NCT05749926 ↗ |